Scientific Publications

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Cell Reports | December 2018

BION-1301 Blocks APRIL-Induced Anti-Apoptotic Signaling, Immune Suppressive Phenotype, and Chemokine Production Associated with Multiple Myeloma
American Society of Hematology Annual Meeting | December 2018

APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-BCMA Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of BION-1301 As a Novel Therapeutic Approach in MM
American Society of Hematology Annual Meeting | December 2018

ADU-S100 Combines with Checkpoint Blockade to Elicit an Anti-Tumor CD8+ T Cell Response to Control Non-Injected Tumors in Preclinical Models
American Association for Cancer Research Tumor Immunology and Immunotherapy Meeting | November 2018

Pan-Allele Anti-SIRPα Antibodies That Block The SIRPα–CD47 Innate Immune Checkpoint
The Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 2018

Phase I Dose-finding Study of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced Solid Tumors or Lymphomas
The Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 2018

SIRPα Blockade Increases the Activity of Multiple Myeloid Lineage Cells and Aids in Remodeling the Tumor Microenvironment
The Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 2018

ADU-S100 Combines with Checkpoint Inhibition to Elicit an Anti-Tumor CD8+ T Cell Response to Control Non-Injected Tumors
The Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 2018

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
Springer Nature | August 2018

Intratumoral Activation of STING with a Synthetic Cyclic Dinucleotide Elicits Anti-Tumor CD8+T-cell Immunity that Effectively Combines with Checkpoint Inhibitors
American Association for Cancer Research Annual Meeting | April 2018

Assessment of pharmacology and toxicology of anti-CTLA-4 antibody (ADU-1604) in non-human primates and evaluation of local anti-CTLA-4 application
American Association for Cancer Research Annual Meeting | April 2018

Preclinical pharmacokinetics, pharmacodynamics and safety of BION-1301, a first-in-class antibody targeting APRIL for the treatment of multiple myeloma
American Association for Cancer Research Annual Meeting | April 2018

BION-1301, a First-in-class APRIL Neutralizing Antibody for the Treatment of Multiple Myeloma: Preclinical Safety, and Analysis of Pharmacokinetics - Pharmacodynamics Relationship
American Society of Hematology Annual Meeting | December 2017

A heterologous prime-boost vaccination strategy combining a listeria and DNA-based vaccine encoding prostatic acid phosphatase (PAP) elicits a strong antigen-specific, anti-tumor response.
The Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 2017

Cellular and genomic disease signature of peripheral blood mononuclear cells in patients with malignant pleural mesothelioma
The Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 2017

Characterization of a novel differentiated anti-CTLA-4 antibody (ADU-1604) in vitro and in vivo
The Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 2017

Development of a first in class APRIL Fully Blocking Antibody BION-1301 for the Treatment of Multiple Myeloma
American Association for Cancer Research Annual Meeting | April 2017

Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (mPDA) (ECLIPSE Study)
American Society of Clinical Oncology – Gastrointestinal Cancer Symposium | January 2017

The host STING pathway at the interface of cancer and immunity
Journal of Clinical Investigation | July 2016

STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia
Cell Reports | June 2016

CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
Cancer Res | May 2016

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA
Journal of Immunology | April 2016

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Blood | April 2016

Haplotyping germline and cancer genomes with high-throughput linked-read sequencing
Nature Biotechnology | March 2016

Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Clinical Cancer Research | March 2016

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors
Cancer Res | January 2016

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
Blood | January 2016

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Cell Reports | May 2015

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Science Translational Medicine | May 2015

Circulating APRIL levels are correlated with advanced disease and prognosis in rectal cancer patients.
Nature | January 2015

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Journal of Clinical Oncology | January 2015

Glutathione activates virulence gene expression of an intracellular pathogen
Nature | January 2015

Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis.
Oncoimmunology | May 23, 2014

Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants.
SAGE Journals | Oct 10, 2013

Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation.
Journal of Experimental Medicine | May 6, 2013

Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the flumist vaccine.
Journal of Immunology | April 15, 2013

Killed but metabolically active vaccines.
Current Opinion in Biotechnology | Dec 23, 2012

Clinical development of Listeria monocytogenes–based immunotherapies.
Seminars in Oncology | June 2012

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase 1 studies of safety and immune induction.
Clinical Cancer Research | Feb 1, 2012

Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases.
Annals of Surgical Oncology | July 2012

The impact of pre-existing memory on differentiation of newly recruited naive CD8 T cells.
Journal of Immunology | Sept 15, 2011

Listeria monocytogenes engineered to activate the Nlrc4 inflammasome are severely attenuated and are poor inducers of protective immunity.
PNAS | July 26, 2011

Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas Blood.
Blood | April 2011

Interplay between CD8a dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses.
PLoS ONE | April 29, 2011

Dynamic imaging of the effector immune response to listeria infection in vivo.
PLoS Pathogens | March 24, 2011

Invasive extravillous trophoblasts restrict intracellular growth and spread of Listeria monocytogenes.
PLoS Pathogens | March 3, 2011

Adjuvants for cancer vaccines.
Seminars in Oncology | June 2010

Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Journal of Immunotherapy | October 2009

Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria.
PLoS Pathogens | September 4, 2009

Impact of preexisting vector-specific immunity on vaccine potency...
Infect. Immun. | June 2009

Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Journal of Immunotherapy | October 2009

Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.
Infect. Immun. | April 2009

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.
Journal of Clinical Investigation | December 2008

Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria.
PNAS | June 6, 2008

Short-term genome evolution of Listeria monocytogenes in a non-controlled environment.
BioMed Central | November 2008

Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.
Expert Review of Vaccines | September 2008

Constitutive Activation of the PrfA Regulon Enhances the Potency of Vaccines Based on Live-Attenuated and Killed but Metabolically Active Listeria monocytogenes Strains
Infect. Immun. | April 2008

Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity.
PNAS | May 2008

Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.
J Immunol 2007

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
Blood | July 1, 2007

Cytosolic entry controls CD8 + T cell potency during bacterial infection.
Infect. Immun. | November 2007

Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.
Nature | January 2006

Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.
Cancer Res | January 15, 2006

Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity
Nature | July 2005

Vaccine wakes from the dead. [Comment on Brockstedt et al. 2005]
NCBI | September 2005

Listeria-based cancer vaccines that segregate immunogenicity from toxicity.
PNAS | August 16, 2004

Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes.
J. Exp. Med. | August 16, 2004

Listeria monocytogenes as a vaccine vector: Virulence attenuation or existing anti-vector immunity does not diminish therapeutic efficacy
J Immunol 2004